Skip to main content

Chenyu Lin

Assistant Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy

Overview


Hematologic oncologist with an interest in cellular therapies and digital health.

Fellowship: Duke Cancer Institute
Residency: Northwestern University
Medical School: University of Chicago Pritzker School of Medicine
Undergraduate: Yale University

Current Appointments & Affiliations


Assistant Professor of Medicine · 2023 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine
Member of the Duke Cancer Institute · 2023 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published October 2, 2024
Decitabine Demonstrates Therapeutic Potential for the Treatment of Myelofibrosis
Published August 5, 2024
KRAS G12C in Veterans with NSCLC Has Favorable Outcomes Compared to Non-G12C Variants; Availability of Sotorasib Treatment Credited
Published May 29, 2023
VA Demonstrates Success in Remote Treatment of Aggressive Cancers

View All News

Recent Publications


Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Journal Article Blood Cancer J · May 9, 2025 Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 part ... Full text Link to item Cite

Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.

Journal Article Bone Marrow Transplant · April 12, 2025 Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17-55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effe ... Full text Link to item Cite
View All Publications

Recent Grants


Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft versus Host Disease

Clinical TrialPrincipal Investigator · Awarded by Rigel Pharmaceuticals, Inc. · 2024 - 2029

Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft versus Host Disease

Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2024 - 2029

View All Grants

Education, Training & Certifications


The University of Chicago · 2016 M.D.

External Links


LinkedIn Twitter